• 1
    Van Dyke TE. The management of inflammation in periodontal disease. J Periodontol 2008;79(Suppl 8):16011608.
  • 2
    Kantarci A, Van Dyke TE. Resolution of inflammation in periodontitis. J Periodontol 2005;76:21682174.
  • 3
    Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255258.
  • 4
    Jeffcoat MK, Williams RC, Reddy MS, English R, Goldhaber P. Flurbiprofen treatment of human periodontitis: effect on alveolar bone height and metabolism. J Periodontal Res 1988;23:381385.
  • 5
    Nyman S, Schroeder HE, Lindhe J. Suppression of inflammation and bone resorption by indomethacin during experimental periodontitis in dogs. J Periodontol 1979;50:450461.
  • 6
    Williams RC, Jeffcoat MK, Kaplan ML, Goldhaber P, Johnson HG, Wechter WJ. Flurbiprofen – a potent inhibitor of bone resorption in beagles. Science 1984;227:640642.
  • 7
    Flemming TF, Rumetsch M, Klaiber B. Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase –α1- proteinase inhibitor in gingival crevicular fluid. J Clin Periodontol 1996;23:153159.
  • 8
    Heasman PA, Seymour RA. An association between long-term non-steroidal anti-inflammatory drug therapy and the severity of periodontal disease. J Clin Periodontol 1990;17:654658.
  • 9
    Kantarci A, Hasturk H, Van Dyke TE. Host-mediated resolution of inflammation in periodontal diseases. Periodontol 2000 2006;40:144163.
  • 10
    Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 2005;73:141162.
  • 11
    Van Dyke TE. Control of inflammation and periodontitis. Periodontol 2000 2007;45:158166.
  • 12
    Kim DM, Koszeghy KL, Badovinac RL, Kawai T, Hosokawa I, Howell TH. The effect of aspirin on gingival crevicular fluid levels of inflammatory and anti-inflammatory mediators in patients with gingivitis. J Periodontol 2007;78:16201626.
  • 13
    Underwood MJ, More RS. The aspirin papers: aspirin benefits patients with vascular disease and those undergoing revascularization. BMJ 1994;308:7172.
  • 14
    Diener HC. Use of acetylsalicylic acid in secondary prevention of stroke. Int J Clin Pract 1998;52:1215.
  • 15
    Drouganis A, Hirsch R. Low-dose aspirin therapy and periodontal attachment loss in ex- and non-smokers. J Clin Periodontol 2001;28:3845.
  • 16
    New York Heart Association. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Circulation 1994;90:644645.
  • 17
    Greene JC, Vermillion JR. The simplified oral hygiene index. J Am Dent Assoc 1964;68:713.
  • 18
    Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J 1975;25:229235.
  • 19
    Paquette DW, Williams RC. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontol 2000 2000;24:239252.
  • 20
    Gary A, Green MD. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone 2001;3:5059.
  • 21
    Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease. JAMA 2007;297:20182024.
  • 22
    Demmer RT, Desvarieux M. Periodontal infections and cardiovascular disease: the heart of the matter. J Am Dent Assoc 2006;137:14S20S.
  • 23
    Meurman JH, Sanz M, Janket MS. Oral health, atherosclerosis, and cardiovascular disease. Crit Rev Oral Biol Med 2004;15:430413.
  • 24
    Royzman D, Recio L, Badovinac RL, et al. The effect of aspirin intake on bleeding on probing in patients with gingivitis. J Periodontol 2004;75:679684.
  • 25
    Schrodi J, Recio L, Fiorellini J, Howell H, Goodson M, Karimbux NY. The effect of aspirin on periodontal parameter bleeding on probing. J Periodontol 2002;73:871876.
  • 26
    Page RC, Eke PI. Case definitions for use in population-based surveillance of periodontitis. J Periodontol 2007;78:13871399.